Cg Oncology [CGON] vs Praxis Precision [PRAX] Detailed Stock Comparison

Cg Oncology, Inc.

NASDAQ
Loading...

Praxis Precision Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Cg Oncology, Inc. wins in 8 metrics, Praxis Precision Medicines Inc. wins in 6 metrics, with 0 ties. Cg Oncology, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Cg Oncology, Inc. Praxis Precision Medicines Inc. Better
Price-to-Book Ratio 7.49 9.46 Cg Oncology, Inc.
Debt-to-Equity Ratio 0.93 0.01 Praxis Precision Medicines Inc.
PEG Ratio -35.48 -38.31 Cg Oncology, Inc.
EV/EBITDA -27.28 -26.32 Praxis Precision Medicines Inc.
Profit Margin (TTM) -15.02% 0.00% Praxis Precision Medicines Inc.
Operating Margin (TTM) -2,097.33% 0.00% Praxis Precision Medicines Inc.
Return on Equity -21.67% -45.83% Cg Oncology, Inc.
Return on Assets (TTM) -15.42% -28.69% Cg Oncology, Inc.
Free Cash Flow (TTM) $-132.48M $-249.12M Cg Oncology, Inc.
1-Year Return 143.13% 807.83% Praxis Precision Medicines Inc.
Price-to-Sales Ratio (TTM) 1,460.48 N/A N/A
Enterprise Value $5.17B $8.58B Praxis Precision Medicines Inc.
EV/Revenue Ratio 1,278.51 N/A N/A
Gross Profit Margin (TTM) -32.21% N/A N/A
Revenue per Share (TTM) $0 N/A N/A
Earnings per Share (Diluted) $-2.08 $-13.48 Cg Oncology, Inc.
Beta (Stock Volatility) 0.71 2.97 Cg Oncology, Inc.
Short % of Float 13.14% 14.21% Cg Oncology, Inc.

Cg Oncology, Inc. vs Praxis Precision Medicines Inc. Stock Performance Analysis

Loading Price Chart...

CGON
PRAX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Cg Oncology, Inc.-2.00%-10.49%-19.62%-10.12%27.72%30.22%
Praxis Precision Medicines Inc.8.08%-21.90%-17.38%-12.35%49.84%-2.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Cg Oncology, Inc.143.13%77.82%77.82%77.82%77.82%77.82%
Praxis Precision Medicines Inc.807.83%2,210.03%21.08%-16.07%-16.07%-16.07%

Performance & Financial Health Analysis: Cg Oncology, Inc. vs Praxis Precision Medicines Inc.

MetricCGONPRAX
Market Information
Market Cap i$5.90B$9.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,186,654391,453
90 Day Avg. Volume i1,518,078416,321
Last Close$54.42$278.93
52 Week Range$23.65 - $75.50$37.19 - $366.52
% from 52W High-27.92%-23.90%
All-Time High$75.50 (May 14, 2026)$914.27 (Jan 04, 2021)
% from All-Time High-27.92%-69.49%
Growth Metrics
Quarterly Revenue Growth4.09%N/A
Quarterly Earnings Growth4.09%-1.00%
Financial Health
Profit Margin (TTM) i-0.15%0.00%
Operating Margin (TTM) i-20.97%0.00%
Return on Equity (TTM) i-0.22%-0.46%
Debt to Equity (MRQ) i0.930.01
Cash & Liquidity
Book Value per Share (MRQ)$9.33$34.85
Cash per Share (MRQ)$8.79$21.52
Operating Cash Flow (TTM) i$-132,346,000$-249,068,000
Levered Free Cash Flow (TTM) i$-87,615,752$-146,253,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Cg Oncology, Inc. vs Praxis Precision Medicines Inc.

MetricCGON (Apr 24, 2026)PRAX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/AN/A
Forward P/E i-35.48-38.31
PEG Ratio i-35.48-38.31
Price to Sales (TTM) i1,460.48N/A
Price to Book (MRQ) i7.499.46
Market Capitalization
Market Capitalization i$5.90B$9.60B
Enterprise Value i$5.17B$8.58B
Enterprise Value Metrics
Enterprise to Revenue i1,278.51N/A
Enterprise to EBITDA i-27.28-26.32
Risk & Other Metrics
Beta i0.712.97
Book Value per Share (MRQ) i$9.33$34.85

Financial Statements Comparison: Cg Oncology, Inc. vs Praxis Precision Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCGON (2025)PRAX (2025)
Revenue/Sales i4.04M0
Cost of Goods Sold i4.65MN/A
COGS % of Revenue i115.0%-
Gross Profit i-607,000N/A
Gross Margin i-15.0%-
Research & Development i116.64M267.12M
Operating Income (EBIT) i-190.77M-326.20M
Operating Margin i-4,722.1%-
EBITDA i-189.33M-326.06M
EBITDA Margin i-4,686.4%-
Pre-Tax Income i-161.00M-303.27M
Pre-Tax Income % of Revenue i-3,985.0%-
Income Tax iN/AN/A
Income Tax % of Revenue i0.0%-
Net Income (Profit) i-161.00M-303.27M
Profit Margin i-3,985.0%-

Balance Sheet & Liquidity Metrics

MetricCGON (2025)PRAX (2025)
Cash & Equivalents i32.49M357.33M
Total Current Assets i759.48M610.91M
Total Current Assets % of Revenue i18,798.9%-
Total Current Liabilities i30.84M59.77M
Total Current Liabilities % of Revenue i763.3%-
Long-Term Debt i6.11M0
Long-Term Debt % of Revenue i151.1%-
Total Shareholders Equity i752.60M878.14M
Retained Earnings i-378.98M-1.14B
Retained Earnings % of Revenue i-9,380.6%-
Property, Plant & Equipment i9.95M415,000

Cash Flow Statement Comparison

MetricCGON (2025)PRAX (2025)
Operating Cash Flow i-138.09M-257.32M
Operating Cash Flow % of Revenue i-3,418.0%-
Capital Expenditures i-134,000-56,000
Free Cash Flow i-132.48M-249.12M
FCF Margin i-3,279.2%-
Debt Repayment i0N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricCGONPRAX
Shares Short i10.54M3.95M
Short Ratio i6.549.07
Short % of Float i13.14%14.21%
Shares Outstanding i80.69M25.20M
Float Shares i69.04M25.78M
% Held by Insiders i0.65%0.40%
% Held by Institutions i110.50%106.12%
% Held by Public i-11.15%-6.52%

Dividend Analysis & Yield Comparison: Cg Oncology, Inc. vs Praxis Precision Medicines Inc.

MetricCGONPRAX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A